Publications and Presentations
| EVENT | DATE | SUBJECT |
|---|---|---|
| American College of Rheumatology (ACR) Convergence 2024 | November 16, 2024 |
C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases |
| Annual J.P. Morgan Healthcare Conference | January 10, 2024 | Corporate Presentation and Clinical Trial Updates |
| ASH Annual Meeting & Exposition | December 11, 2023 |
C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up |
| December 9, 2023 |
Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy |
|
| AACR Annual Meeting | April 14, 2023 |
First report of preliminary safety, efficacy, and pharmacokinetics of C-CAR031 (GPC3-specific TGFβRIIDN CAR-T) in patients with advanced HCC |
| Journal for Immunotherapy of Cancer | September, 2022 |
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma |